Coloplast Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Kristian Villumsen
Chief executive officer
DKK 22.0m
Total compensation
CEO salary percentage | 55.9% |
CEO tenure | 6yrs |
CEO ownership | 0.04% |
Management average tenure | 6.3yrs |
Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Dec 04Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?
Nov 29Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Nov 13Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Nov 08Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Oct 18Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 23Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?
Aug 22Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price
Jul 17These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Jun 29Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations
May 21Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00
May 10Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report
May 09A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)
Apr 26There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price
Apr 08Is Coloplast (CPH:COLO B) A Risky Investment?
Mar 21Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)
Jan 09Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings
Dec 22CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | DKK 22m | DKK 12m | DKK 5b |
Jun 30 2024 | n/a | n/a | DKK 5b |
Mar 31 2024 | n/a | n/a | DKK 5b |
Dec 31 2023 | n/a | n/a | DKK 5b |
Sep 30 2023 | DKK 23m | DKK 12m | DKK 5b |
Jun 30 2023 | n/a | n/a | DKK 5b |
Mar 31 2023 | n/a | n/a | DKK 5b |
Dec 31 2022 | n/a | n/a | DKK 5b |
Sep 30 2022 | DKK 21m | DKK 12m | DKK 5b |
Jun 30 2022 | n/a | n/a | DKK 5b |
Mar 31 2022 | n/a | n/a | DKK 5b |
Dec 31 2021 | n/a | n/a | DKK 5b |
Sep 30 2021 | DKK 22m | DKK 11m | DKK 5b |
Jun 30 2021 | n/a | n/a | DKK 5b |
Mar 31 2021 | n/a | n/a | DKK 4b |
Dec 31 2020 | n/a | n/a | DKK 4b |
Sep 30 2020 | DKK 20m | DKK 11m | DKK 4b |
Jun 30 2020 | n/a | n/a | DKK 4b |
Mar 31 2020 | n/a | n/a | DKK 4b |
Dec 31 2019 | n/a | n/a | DKK 4b |
Sep 30 2019 | DKK 17m | DKK 10m | DKK 4b |
Jun 30 2019 | n/a | n/a | DKK 4b |
Mar 31 2019 | n/a | n/a | DKK 4b |
Dec 31 2018 | n/a | n/a | DKK 4b |
Sep 30 2018 | DKK 11m | DKK 6m | DKK 4b |
Compensation vs Market: Kristian's total compensation ($USD3.09M) is about average for companies of similar size in the Danish market ($USD4.10M).
Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.
CEO
Kristian Villumsen (54 yo)
6yrs
Tenure
DKK 22,000,000
Compensation
Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President & CEO | 6yrs | DKK 22.00m | 0.045% DKK 81.1m | |
Executive VP & CFO | 10.4yrs | DKK 11.30m | 0.0012% DKK 2.1m | |
Executive Vice President of Global Operations | 10.4yrs | DKK 9.90m | 0.011% DKK 20.4m | |
Executive Vice President of Chronic Care | no data | DKK 9.50m | no data | |
Senior Controller & Employees Representative Director | no data | DKK 450.00k | 0.000020% DKK 36.1k | |
Vice President of Investor Relations | no data | no data | no data | |
Vice President of Corporate Communications | no data | no data | no data | |
Executive Vice President of People & Culture | 2.9yrs | no data | no data | |
Senior Vice President of Sales Europe | 12.7yrs | no data | no data | |
Executive Vice President of Voice & Respiratory Care | less than a year | no data | no data | |
Senior Vice President of Wound & Skin Care | 4.3yrs | no data | no data | |
Senior Vice President of Chronic Care - North America | 6.7yrs | no data | no data |
6.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: COLO B's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Senior Controller & Employees Representative Director | 18.9yrs | DKK 450.00k | 0.000020% DKK 36.1k | |
Independent Director | 7yrs | DKK 690.00k | 0.0027% DKK 4.8m | |
Independent Chairman of the Board | 6yrs | DKK 1.84m | 0.0054% DKK 9.7m | |
Deputy Chairman | 56.9yrs | DKK 938.00k | 1.93% DKK 3.5b | |
Independent Director | 4yrs | DKK 880.00k | 0.00022% DKK 396.7k | |
Independent Director | 9yrs | DKK 600.00k | no data | |
Employees Representative Director | 6.9yrs | DKK 450.00k | no data | |
Employees Representative Director | 6.9yrs | DKK 450.00k | 0.00072% DKK 1.3m | |
Independent Director | 3yrs | DKK 600.00k | no data |
6.9yrs
Average Tenure
59yo
Average Age
Experienced Board: COLO B's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 09:26 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Coloplast A/S is covered by 49 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Morten Larsen | ABG Sundal Collier |
Kamla Singh | AlphaValue |
Robert Bate | Barclays |